-visual analog scale satisfaction in post-therapeutic. Results.-Among the 52 patients treated 64% were male, 37% are children aged 5 to 15 years. Hemiplegia and cerebral palsy represent 73% of diseases treated. The equine foot was treated in 54% of cases where a percentage of 64% muscle toxins represented by the triceps surae (42% of gastrocnemius, soleus 21%). Before treatment, the mean VAS pain was 6.85, the average Ashworth was 3.1, the mean range of motion (dorsiflexion of the ankle) was À78. After treatment, the mean VAS pain increased to 4.02 that of Ashworth 2, and the mean joint amplitudes increased to 1.58. Discussion.-The results obtained after injection of botulinum toxin in these 52 patients were satisfactory standard analgesic, hypertonic and joint mobility, by a regression of pain intensity estimated at three points on average, a regression point of the spasticity and a gain of passive joint movement of 8.58 on average. These results have led to an improvement in the lives of patients at the functional level with an average of 53.63% EVA satisfaction. Conclusion.-Focal spasticity is causing functional impairment of a major source of pain and muscle-tendon and articular use of botulinum toxin has dramatically improved the lives of these 52 patients, hence the interest to generalize this method therapeutic. (Robertson et al., 2009). However, the mechanisms behind these benefits are still unknown. The aim of this study was to compare the analytical effect of BTX-A in the RF muscle (passive stretch and voluntary strength assessed by an isokinetic dynamometer) and functional repercussions on gait (assessed by three-dimensional motion analysis) in spastic hemiparetic patients with stiff knee gait (SKG) caused by RF spasticity. Methods.-Ten stroke patients with SKG caused by RF spasticity were included and evaluated before and after a BTX-A injection in RF. Analytical evaluations consisted of: (i) a clinical examination; (ii) an assessment using an isokinetic dynamometer with surface electromyography (in order to quantify passive stretch and knee flexor and extensor voluntary strength; (iii) a three-dimensional motion analysis gait assessment (in order to quantify spatiotemporal and kinematic gait parameters).
Generalized fatigue after Botulinum neurotoxin A (BoN-
Results.-Mean jitter, percentage of pathologic fibers and conduction blocks for asymptomatic patients differs from those of patients presenting distant muscular deficit (P = 0.0001) and patients suffering botulism (P = 0.017). Mean jitter and number of conduction blocks differs between patients presenting unusual fatigue and patients presenting distant muscular deficit (P = 0.0005). No significant difference appears between asymptomatics and patients relating unusual fatigue after BoNTA treatment.
Discussion.-This study doesn't give rise to generalized BoNTA diffusion in patients reporting unusual fatigue after BoNTA treatment although jitter clearly differs between patients presenting distant muscle weakness and control group. Generalized neuromuscular disorder doesn't seem to explain those fatigue events. Several hypotheses can account for it: not enough patients in the group reporting unusual fatigue, fatigue could be due to autonomic nervous system disorder that is not explored with this single fiber EMG, immune mechanism. Fatigue could be reported to initial disease. Methods.-Ten stroke patients with SKG caused by RF spasticity were included and evaluated before and after a BTX-A injection in RF. Analytical evaluations consisted of: (i) a clinical examination; (ii) an assessment using an isokinetic dynamometer with surface electromyography (in order to quantify passive stretch and knee flexor and extensor voluntary strength; (iii) a three-dimensional motion analysis gait assessment (in order to quantify spatiotemporal and kinematic gait parameters).
Results.-One month after BTX-A injection in RF, the following results were found: (i) a decrease in knee extensor strength and an increase in knee flexor strength; (ii) no change in the intensity of extensor activity during passive stretch; (iii) an increase in the angle at which the stretch reflex occurred. 3D analyses showed an increase in gait speed, which was related to an increase in cadence and an increase in peak knee flexion during swing phase.
Discussion.-The improvement in knee flexion following BTX-A injection in RF seems to be related to an increase in the angle at which the stretch reflex occurs with no change in intensity of the contraction. This change in the threshold of the sensitivity of neuromuscular spindles infers that BTX-A affects the motoneuron g-neuromuscular spindle synapse (Trompetto et al., 2006 Objective.-To compare the effect of BoNTA on voluntary and stretch reflexrelated torque (and angle at peak torque) produced by activation of the rectus femoris (RF) muscle. Methods.
-A prospective open pilot study. n = 15 incomplete SCI patients, impaired by a specific RF spasticity (n = 20), with RF hyperactivity in midswing and a stiff-knee-gait quantified by formal Gait Analysis (GA), were assessed before and after BoNTA injection (Botox, 200 UI). Main outcome
